Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000574936 | SCV000662725 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-06-10 | criteria provided, single submitter | clinical testing | The p.V172A variant (also known as c.515T>C), located in coding exon 5 of the NBN gene, results from a T to C substitution at nucleotide position 515. The valine at codon 172 is replaced by alanine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV001800771 | SCV002045189 | uncertain significance | Microcephaly, normal intelligence and immunodeficiency | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476214 | SCV002778745 | uncertain significance | Microcephaly, normal intelligence and immunodeficiency; Aplastic anemia; Acute lymphoid leukemia | 2021-10-21 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004691922 | SCV005196019 | uncertain significance | not provided | criteria provided, single submitter | not provided |